NCT00352079 2023-08-04
BCG With or Without Gefitinib in Treating Patients With High-Risk Bladder Cancer
Canadian Cancer Trials Group
Phase 3 Terminated
Clinical Trials
10 trialsNCT00025116 2020-04-06
ZD 1839 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
Canadian Cancer Trials Group
Phase 2 Completed
NCT00467077 2017-03-17
Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
California Cancer Consortium
Phase 2 Terminated
NCT00066378 2013-10-24
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00014144 2012-10-08
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
SWOG Cancer Research Network
Phase 2 Completed
NCT00052754 2012-09-24
Gefitinib in Treating Patients With Locally Advanced or Metastatic Synovial Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00066339 2012-07-18
Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00091156 2012-07-16
Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Terminated
NCT00103051 2012-07-16
Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00052169 2007-12-18
Therapy With Docetaxel and ZD1839 for Patients Who Have Advanced Breast Cancer
NSABP Foundation Inc
Phase 2 Completed